McKesson Corp Files Definitive Proxy Statement

TL;DR

McKesson filed its proxy statement - shareholders vote soon on exec pay & board.

AI Summary

McKesson Corporation filed a Definitive Proxy Statement (DEFA14A) on July 8, 2024. This filing is related to the company's annual meeting and likely concerns the election of directors, executive compensation, and other corporate governance matters. The filing is made under the Securities Exchange Act of 1934.

Why It Matters

This filing provides shareholders with crucial information regarding company governance, executive pay, and voting matters, enabling them to make informed decisions at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) for a public company, not indicating any immediate financial distress or unusual events.

Key Players & Entities

• MCKESSON CORP (company) — Registrant
• 0000927653-24-000076 (filing_id) — Accession Number
• 20240708 (date) — Filing Date
• 6555 STATE HIGHWAY 161 (address) — Business Address
• IRVING (city) — Business Address City
• TX (state) — Business Address State
• 75039 (zip_code) — Business Address Zip
• 972-446-4800 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $8.8B — creased value to biopharma and enabled >$8.8B in prescription savings Network of 950,
• $309B — Priorities FY24 Financial Highlights(1) $309B Total Revenue $3.3B Cash Returned to Sh
• $3.3B — ncial Highlights(1) $309B Total Revenue $3.3B Cash Returned to Shareholders $4.3B Ope
• $4.3B — nue $3.3B Cash Returned to Shareholders $4.3B Operating Cash Flow (1) Full fiscal yea
• $22.39 — everage, execute, advance, and develop. $22.39 Earnings per Diluted Share Focus on G

Filing Documents

• mck-2024xdefa14axroadshowa.htm (DEFA14A) — 29KB
• a06_428123-1xlogoxmcka.jpg (GRAPHIC) — 86KB
• image_0.jpg (GRAPHIC) — 20KB
• mck_2024proxyseasonroads001.jpg (GRAPHIC) — 70KB
• mck_2024proxyseasonroads002.jpg (GRAPHIC) — 140KB
• mck_2024proxyseasonroads003.jpg (GRAPHIC) — 158KB
• mck_2024proxyseasonroads004.jpg (GRAPHIC) — 176KB
• mck_2024proxyseasonroads005.jpg (GRAPHIC) — 172KB
• mck_2024proxyseasonroads006.jpg (GRAPHIC) — 178KB
• mck_2024proxyseasonroads007.jpg (GRAPHIC) — 214KB
• mck_2024proxyseasonroads008.jpg (GRAPHIC) — 183KB
• mck_2024proxyseasonroads009.jpg (GRAPHIC) — 199KB
• mck_2024proxyseasonroads010.jpg (GRAPHIC) — 120KB
• 0000927653-24-000076.txt ( ) — 2394KB

From the Filing

MCK-2024-DEFA14A-Roadshow UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 McKESSON CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. Summer Governance Roadshow ----------- 2024 Annual Meeting of Shareholders 2 Advancing Health Outcomes for All® Strength in Distribution 99% pharmaceutical order accuracy in North America 285,000+ customers served with medical-surgical products Leading distributor in oncology and specialty therapies Technology Differentiation Connected to payers representing 94% of U.S. prescription volume Access to research data from >2.4M patient records including >85 oncology indications Biopharma Services More than 650 biopharma brands served Increased value to biopharma and enabled >$8.8B in prescription savings Network of 950,000 providers and over 50,000 pharmacies Superior Specialty Assets 1.4+ million patients annually treated by The US Oncology Network physicians +1,000 clinical trials actively enrolling Supported 95% of therapeutic areas 40M+ pharmaceutical and medical supply deliveries annually 3 Progressing on Our Company Priorities Focus on People and Culture Commitment to investing in talent Recognized as one of America's Greatest Workplaces for Diversity in 2024(2) Live through I2CARE values and stay grounded in the ILEAD leadership principles(3) Evolve and Grow the Portfolio Digital enablement and AI Technology modernization and process simplification Acquired Compile, Inc., a healthcare data platform that provides insights for biopharma companies Expand Oncology and Biopharma Platforms Differentiated assets and capabilities in community oncology Leadership in access, affordability, and adherence solutions Growth to support approximately 2,600 providers spanning 600 sites in 31 states Drive Sustainable Core Growth Scaled and durable distribution capabilities Leading pharmaceutical and medical supply networks Integrating artificial intelligence (AI) and machine learning Our Company Priorities FY24 Financial Highlights(1) $309B Total Revenue $3.3B Cash Returned to Shareholders $4.3B Operating Cash Flow (1) Full fiscal year 2024 (April 1, 2023 to March 31, 2024). (2) Newsweek. (3) I2CARE represents integrity, inclusion, customer-first, accountability, respect, and excellence. ILEAD represents inspire, leverage, execute, advance, and develop. $22.39 Earnings per Diluted Share Focus on Good Corporate GovernanceShareholder Engagement in FY 2024 Key Themes Discussed Recent McKesson Actions Board Composition Sustainability Metrics in Executive Compensation Human Capital Management Emissions Reduction Targets Board Skills and Diversity Board Evaluations Management Succession Planning - Elected Deborah Dunsire, M.D. and Kevin M. Ozan to the Board in 2024 - Both appointees collectively bring valuable senior executive leadership experience and supplement the Board's skills in healthcare, finance, accounting, M&A and risk management - Introduced sustainability priorities as a discretionary, downward modifier in the Management Incentive Plan in FY 2023 - Continued focus on delivering our Employee Value Proposition – providing meaningful work, demonstrating care for our employees and ensuring a culture of belonging - Received SBTi approval of our climate change targets in FY 2023 - Providing updates on progress to meeting our goals in shareholder engagements efforts and FY 2024 Impact Report - Enhanced Board skills matrix to link experience and skills to strategic priorities - Recruited 8 directors, including 4 women and/or 4 racially or ethnically diverse directors, in the past 5 years - Board evaluations conducted by independent third-party facilitator in FY 2023 - Provided feedback on effectiveness and considerations for strengthening Board oversight - Appointed new EVP, Chief Legal Officer, Michele Lau, and EVP, CIO and CTO, Francisco Fraga - Both bring significant leadership and depth of experience to their respective positions McKesson reached out to shareholders representing over 51% of our outstanding common stock and engaged with approximately 33%. The below table reflects key topics discussed and recent relevant updates 4 5 Oversight from Our Experienced and Diverse Board Our director nominees have a mix of background

View Full Filing

View this DEFA14A filing on SEC EDGAR